NO20003692D0 - Bisulfat-salt av HIV-protease-inhibitor - Google Patents

Bisulfat-salt av HIV-protease-inhibitor

Info

Publication number: NO20003692D0
Authority: NO; Norway
Prior art keywords: protease inhibitor; hiv protease; bisulfate salt; bisulfate; salt
Prior art date: 1998-01-20

Application number

NO20003692A

Other languages

English (en)

Other versions

NO20003692L (no

NO315605B1 (no

Inventor

Janak Singh

Pudipeddi Madhusudhan

Mark D Lindrud

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-20

Filing date

2000-07-19

Publication date

2000-07-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003692(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-07-19 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2000-07-19 Publication of NO20003692D0 publication Critical patent/NO20003692D0/no

2000-07-19 Publication of NO20003692L publication Critical patent/NO20003692L/no

2003-09-29 Publication of NO315605B1 publication Critical patent/NO315605B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20003692A 1998-01-20 2000-07-19 Bisulfat av HIV-protease-inhibitor NO315605B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7196898P	1998-01-20	1998-01-20
PCT/US1998/027382 WO1999036404A1 (en)	1998-01-20	1998-12-22	Bisulfate salt of hiv protease inhibitor

Publications (3)

Publication Number	Publication Date
NO20003692D0 true NO20003692D0 (no)	2000-07-19
NO20003692L NO20003692L (no)	2000-07-19
NO315605B1 NO315605B1 (no)	2003-09-29

Family

ID=22104737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20003692A NO315605B1 (no)	1998-01-20	2000-07-19	Bisulfat av HIV-protease-inhibitor

Country Status (38)

Country	Link
US (1)	US6087383A (no)
EP (1)	EP1056722B1 (no)
JP (2)	JP4860037B2 (no)
KR (1)	KR100559283B1 (no)
CN (1)	CN1116282C (no)
AR (1)	AR014417A1 (no)
AT (1)	ATE219057T1 (no)
AU (1)	AU735875B2 (no)
BG (1)	BG64774B1 (no)
BR (1)	BR9814736A (no)
CA (1)	CA2317736C (no)
CO (1)	CO4970820A1 (no)
CZ (1)	CZ293507B6 (no)
DE (1)	DE69806067T2 (no)
DK (1)	DK1056722T3 (no)
EE (1)	EE04434B1 (no)
EG (1)	EG23936A (no)
ES (1)	ES2178300T3 (no)
GE (1)	GEP20033026B (no)
HU (1)	HU227196B1 (no)
IL (2)	IL137384A0 (no)
LT (1)	LT4780B (no)
LV (1)	LV12522B (no)
MY (1)	MY114838A (no)
NO (1)	NO315605B1 (no)
NZ (1)	NZ504417A (no)
PE (1)	PE20000185A1 (no)
PL (1)	PL190744B1 (no)
PT (1)	PT1056722E (no)
RO (1)	RO118869B1 (no)
RU (1)	RU2186070C2 (no)
SK (1)	SK283975B6 (no)
TR (1)	TR200001876T2 (no)
TW (1)	TW531531B (no)
UA (1)	UA59432C2 (no)
UY (1)	UY25345A1 (no)
WO (1)	WO1999036404A1 (no)
ZA (1)	ZA9956B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA02012560A (es)	2000-06-30	2003-05-14	Elan Pharm Inc	Compuestos para tratar la enfermedad de alzheimer.
JP2004534771A (ja)	2001-05-22	2004-11-18	イーラン　ファーマスーティカルズ、インコーポレイテッド	アザヒドロキシル化エチルアミン化合物
US7193065B2 (en) *	2001-07-13	2007-03-20	Roche Diagnostics Operations, Inc.	Protease inhibitor conjugates and antibodies useful in immunoassay
US7157561B2 (en) *	2001-07-13	2007-01-02	Roche Diagnostics Operations, Inc.	Methods of inhibiting transmission of a costimulatory signal of lymphocytes
EA201100293A1 (ru) *	2003-01-14	2011-08-30	Джилид Сайэнс, Инк.	Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
TW200534879A (en) *	2004-03-25	2005-11-01	Bristol Myers Squibb Co	Coated tablet formulation and method
US7829720B2 (en) *	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
CN1980666B (zh) *	2004-05-04	2011-03-30	布里斯托尔-迈尔斯斯奎布公司	制备阿扎那韦硫酸氢盐的方法和新的形式
US20050256314A1 (en) *	2004-05-04	2005-11-17	Soojin Kim	Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) *	2004-05-19	2005-12-29	Andrew Rusowicz	Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) *	2004-05-28	2011-12-21	Bristol Myers Squibb Co	Coated tablet formulation and method
CA2588466A1 (en) *	2004-12-03	2006-06-08	Merck & Co., Inc.	Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
US7642049B2 (en) *	2006-06-30	2010-01-05	Bristol-Myers Squibb Company	Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
PT2069303E (pt) *	2006-07-21	2016-06-08	Gilead Sciences Inc	Inibidores de protease antiviral
BG66056B1 (bg) *	2006-10-05	2010-12-30	Красимир ДЕЧЕВ	Метод и инсталация за производство на трисезонна добавка към дизелово гориво
BRPI0823520A2 (pt)	2007-06-12	2013-12-17	Concert Pharmaceuticals Inc	Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
ATE500820T1 (de) *	2007-06-22	2011-03-15	Bristol Myers Squibb Co	Tablettierte atazanavirhaltige zusammensetzungen
DK2170292T3 (da) *	2007-06-22	2014-04-07	Bristol Myers Squibb Holdings Ireland	Atazanavirholdige sammensætninger i tabletform
ATE503467T1 (de) *	2007-06-22	2011-04-15	Bristol Myers Squibb Co	Tablettierte atazanavirhaltige zusammensetzungen
ES2360336T3 (es) *	2007-06-22	2011-06-03	Bristol-Myers Squibb Company	Composiciones en comprimidos que contienen atazanavir.
NZ582089A (en) *	2007-06-29	2013-01-25	Gilead Sciences Inc	Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
TW200914011A (en) *	2007-06-29	2009-04-01	Gilead Sciences Inc	Therapeutic compositions and methods
US20110178305A1 (en) *	2008-05-08	2011-07-21	Ranbaxy Laboratories Limited	Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
EP2391350A1 (en)	2008-12-18	2011-12-07	Ranbaxy Laboratories Limited	Atazanavir formulations
US8552036B2 (en)	2009-01-12	2013-10-08	Hetero Research Foundation	Polymorph of atazanavir sulfate
JP2012528160A (ja)	2009-05-27	2012-11-12	メルク・シャープ・エンド・ドーム・コーポレイション	Ｈｉｖプロテアーゼ阻害薬
EP2272830A1 (en)	2009-06-18	2011-01-12	Esteve Química, S.A.	Preparation process of an antivirally heterocyclic azahexane derivative
WO2011027324A1 (en)	2009-09-03	2011-03-10	Ranbaxy Laboratories Limited	Polymorphic forms of atazanavir sulfate
BR112012009857A8 (pt)	2009-10-26	2023-04-11	Merck Sharp & Dohme	Composições farmacêuticas sólidas contendo um inibidor de integrase
WO2011080562A1 (en)	2009-12-29	2011-07-07	Hetero Research Foundation	Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
SMT201800290T1 (it)	2010-01-27	2018-07-17	Viiv Healthcare Co	Terapia antivirale
EP2542527A2 (en)	2010-03-01	2013-01-09	Lupin Limited	Process for the preparation of atazanavir sulfate substantially free of diastereomers
EP2555757B1 (en)	2010-04-09	2016-05-25	Bristol-Myers Squibb Holdings Ireland	Atazanavir sulfate formulations with improved ph effect
WO2012041488A1 (en)	2010-09-28	2012-04-05	Ratiopharm Gmbh	Dry processing of atazanavir
WO2013014633A1 (en)	2011-07-27	2013-01-31	Ranbaxy Laboratories Limited	Process for preparation of atazanavir or its bisulfate salt
US8461347B2 (en)	2011-08-05	2013-06-11	Scinopharm Taiwan, Ltd.	Process for preparing form A of atazanavir sulfate
US9133157B2 (en)	2011-10-26	2015-09-15	Merck Canada Inc.	HIV protease inhibitors
US9382207B2 (en)	2012-08-24	2016-07-05	Laurus Labs Private Limited	Process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) *	2012-09-04	2014-03-13	上海迪赛诺化学制药有限公司	制备阿扎那韦硫酸氢盐a型结晶的方法
ZA201401073B (en)	2013-02-12	2015-12-23	Cipla Ltd	Process for preparing atazanavir sulphate
CN104250223B (zh) *	2013-06-28	2017-04-12	上海威智医药科技有限公司	阿扎那韦氢溴酸盐及其制备和应用
CN104250224A (zh) *	2013-06-28	2014-12-31	上海威智医药科技有限公司	阿扎那韦富马酸盐及其制备和应用
CN104250225A (zh) *	2013-06-28	2014-12-31	上海威智医药科技有限公司	阿扎那韦磷酸盐及其制备和应用
CN105859611A (zh) *	2016-04-18	2016-08-17	上海现代制药海门有限公司	一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) *	2018-10-02	2022-09-23	国药集团川抗制药有限公司	阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) *	2018-12-20	2023-07-14	陕西理工大学	一种阿扎那韦单晶及其制备方法
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI933472A7 (fi) *	1992-08-07	1994-02-08	Sankyo Co	Peptider med foermaoga att inhibera effekten av HIV-proteas, deras framstaellning och terapeutiska anvaendning
US5849911A (en) *	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
TW409125B (en) *	1996-04-22	2000-10-21	Novartis Ag	Antivirally active heterocyclic azahexane derivatives

1998
- 1998-12-21 US US09/217,538 patent/US6087383A/en not_active Expired - Lifetime
- 1998-12-22 PL PL342019A patent/PL190744B1/pl unknown
- 1998-12-22 EP EP98964878A patent/EP1056722B1/en not_active Expired - Lifetime
- 1998-12-22 DE DE69806067T patent/DE69806067T2/de not_active Expired - Lifetime
- 1998-12-22 CN CN98812741A patent/CN1116282C/zh not_active Expired - Lifetime
- 1998-12-22 JP JP2000540121A patent/JP4860037B2/ja not_active Expired - Lifetime
- 1998-12-22 NZ NZ504417A patent/NZ504417A/en not_active IP Right Cessation
- 1998-12-22 CA CA002317736A patent/CA2317736C/en not_active Expired - Lifetime
- 1998-12-22 ES ES98964878T patent/ES2178300T3/es not_active Expired - Lifetime
- 1998-12-22 KR KR1020007007885A patent/KR100559283B1/ko not_active Expired - Fee Related
- 1998-12-22 RU RU2000119792/04A patent/RU2186070C2/ru active
- 1998-12-22 SK SK1062-2000A patent/SK283975B6/sk not_active IP Right Cessation
- 1998-12-22 IL IL13738498A patent/IL137384A0/xx active IP Right Grant
- 1998-12-22 GE GEAP19985466A patent/GEP20033026B/en unknown
- 1998-12-22 EE EEP200000798A patent/EE04434B1/xx unknown
- 1998-12-22 TR TR2000/01876T patent/TR200001876T2/xx unknown
- 1998-12-22 DK DK98964878T patent/DK1056722T3/da active
- 1998-12-22 RO ROA200000717A patent/RO118869B1/ro unknown
- 1998-12-22 CZ CZ20002564A patent/CZ293507B6/cs not_active IP Right Cessation
- 1998-12-22 PT PT98964878T patent/PT1056722E/pt unknown
- 1998-12-22 BR BR9814736-6A patent/BR9814736A/pt not_active Application Discontinuation
- 1998-12-22 AT AT98964878T patent/ATE219057T1/de active
- 1998-12-22 HU HU0101389A patent/HU227196B1/hu unknown
- 1998-12-22 WO PCT/US1998/027382 patent/WO1999036404A1/en not_active Ceased
- 1998-12-22 UA UA2000084931A patent/UA59432C2/uk unknown
- 1998-12-22 AU AU20101/99A patent/AU735875B2/en not_active Expired
1999
- 1999-01-05 MY MYPI99000020A patent/MY114838A/en unknown
- 1999-01-05 ZA ZA9900056A patent/ZA9956B/xx unknown
- 1999-01-12 UY UY25345A patent/UY25345A1/es not_active Application Discontinuation
- 1999-01-15 TW TW088100623A patent/TW531531B/zh not_active IP Right Cessation
- 1999-01-17 EG EG5699A patent/EG23936A/xx active
- 1999-01-18 AR ARP990100179A patent/AR014417A1/es active IP Right Grant
- 1999-01-19 CO CO99002578A patent/CO4970820A1/es unknown
- 1999-01-20 PE PE1999000047A patent/PE20000185A1/es not_active IP Right Cessation
2000
- 2000-06-06 LV LVP-00-78A patent/LV12522B/en unknown
- 2000-07-14 LT LT2000067A patent/LT4780B/lt not_active IP Right Cessation
- 2000-07-17 BG BG104618A patent/BG64774B1/bg unknown
- 2000-07-19 NO NO20003692A patent/NO315605B1/no not_active IP Right Cessation
- 2000-07-19 IL IL137384A patent/IL137384A/en not_active IP Right Cessation
2008
- 2008-12-17 JP JP2008321240A patent/JP2009102357A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ATE219057T1 (de)	2002-06-15
TR200001876T2 (tr)	2000-11-21
EG23936A (en)	2008-01-14
TW531531B (en)	2003-05-11
IL137384A0 (en)	2001-07-24
CN1116282C (zh)	2003-07-30
AR014417A1 (es)	2001-02-28
SK283975B6 (sk)	2004-06-08
BR9814736A (pt)	2000-10-24
NZ504417A (en)	2001-09-28
EP1056722A1 (en)	2000-12-06
JP2009102357A (ja)	2009-05-14
CN1283188A (zh)	2001-02-07
KR20010034221A (ko)	2001-04-25
WO1999036404A1 (en)	1999-07-22
US6087383A (en)	2000-07-11
KR100559283B1 (ko)	2006-03-15
JP2002509136A (ja)	2002-03-26
EE200000798A (et)	2002-06-17
SK10622000A3 (sk)	2001-02-12
DE69806067T2 (de)	2003-01-23
HU227196B1 (en)	2010-10-28
NO20003692L (no)	2000-07-19
HUP0101389A3 (en)	2003-07-28
CA2317736A1 (en)	1999-07-22
LV12522B (en)	2000-10-20
HK1033667A1 (en)	2001-09-14
CZ293507B6 (cs)	2004-05-12
HUP0101389A2 (hu)	2001-08-28
MY114838A (en)	2003-01-31
UA59432C2 (uk)	2003-09-15
EP1056722B1 (en)	2002-06-12
BG64774B1 (bg)	2006-03-31
PL190744B1 (pl)	2006-01-31
AU735875B2 (en)	2001-07-19
EE04434B1 (et)	2005-02-15
BG104618A (en)	2001-02-28
EP1056722A4 (en)	2001-01-10
CO4970820A1 (es)	2000-11-07
ZA9956B (en)	2000-07-05
DK1056722T3 (da)	2002-09-30
JP4860037B2 (ja)	2012-01-25
LT2000067A (en)	2000-11-27
PL342019A1 (en)	2001-05-07
CA2317736C (en)	2004-11-02
UY25345A1 (es)	2000-12-29
LV12522A (en)	2000-08-20
DE69806067D1 (de)	2002-07-18
LT4780B (lt)	2001-04-25
RU2186070C2 (ru)	2002-07-27
GEP20033026B (en)	2003-07-25
RO118869B1 (ro)	2003-12-30
HK1033458A1 (en)	2001-08-31
IL137384A (en)	2006-08-01
PE20000185A1 (es)	2000-05-14
CZ20002564A3 (cs)	2000-10-11
AU2010199A (en)	1999-08-02
NO315605B1 (no)	2003-09-29
PT1056722E (pt)	2002-09-30
ES2178300T3 (es)	2002-12-16

Publication	Publication Date	Title
NO20003692D0 (no)	2000-07-19	Bisulfat-salt av HIV-protease-inhibitor
NO20012980D0 (no)	2001-06-15	Proteaseinhibitorer
DE69823178D1 (de)	2004-05-19	Serine protease inhibitoren
EE200000386A (et)	2001-12-17	Aspartüülproteaasi inhibiitorite eelravimid
AR028253A1 (es)	2003-04-30	Inhibidores de la glucogeno fosforilasa
DE69928195D1 (de)	2005-12-15	Komplettierung von Untrerdruck-Bohrlöchern
NO995433D0 (no)	1999-11-05	Protease-inhibitorer
PT945443E (pt)	2003-06-30	Derivados de pirimidina inibidores de hiv
NO20011966D0 (no)	2001-04-20	Serin-protease-inhibitor
NO20016034D0 (no)	2001-12-10	Inhibitorer av aspartylprotease
NO20004696L (no)	2000-09-20	Kinoloner som serinproteaseinhibitorer
NO995435D0 (no)	1999-11-05	Protease-inhibitorer
NO995434L (no)	1999-11-05	Proteaseinhibitorer
NO995268D0 (no)	1999-10-28	Proteaseinhibitorer
ID28032A (id)	2001-05-03	TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
DK1066276T3 (da)	2003-10-06	Fremgangsmåde til syntese af HIV protease inhibitor
DE60007360D1 (de)	2004-01-29	Amorphe modifikation von torasemid
EE200100017A (et)	2002-06-17	N-tert-butüülhüdroksüülamiini uued soolad
DE69930014D1 (de)	2006-04-27	Wirksame verarbeitung von mehrfachverbindungsverkehr
EP1195163A4 (en)	2004-07-21	Serine protease inhibitors
NO995822D0 (no)	1999-11-26	Sulfatsalt av en HIV-proteaseinhibitor som har forbedret oral absorpsjon og biotilgjengelighet
NO994415L (no)	1999-11-10	HIV proteaseinhibitorer
FI982552A0 (fi)	1998-11-25	Stabilointimenetelmä
MA26429A1 (fr)	2004-12-20	Inhibiteurs de protease

Legal Events

Date	Code	Title	Description
2013-09-23	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH
2015-10-19	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH
2019-01-14	MK1K	Patent expired